Omega Flex Q2 net income falls 35.6% on lower sales; MediTrac gets CE mark
Omega Flex reported lower second-quarter 2026 results, with net sales down 5.8% and net income down 35.6% from a year earlier. The company cited higher raw material costs, including tariffs, along with marketing and certification expenses, and said it expects these costs to continue before normalizing over time. Shareholders also received news that its MediTrac corrugated medical tubing earned EU medical device certification.
Key points
- Three-month net sales were $24,057,000 versus $25,525,000 a year earlier, down 5.8%.
- Three-month net income was $2,675,000 ($0.27 per share) versus $4,156,000 ($0.41 per share), down 35.6%.
- Six-month net income was $4,752,000 ($0.47 per share) versus $7,724,000 ($0.77 per share), down 38.5%.
- MediTrac CMT received CE mark under EU MDR 2017/745 as a Class IIa medical device in August 2026.
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.